Neurocognitive function in patients with recurrent glioblastoma treated with bevacizumab Journal Article

Authors: Wefel, J. S.; Cloughesy, T.; Zazzali, J. L.; Zheng, M.; Prados, M.; Wen, P. Y.; Mikkelsen, T.; Schiff, D.; Abrey, L. E.; Alfred Yung, W. K.; Paleologos, N.; Nicholas, M. K.; Jensen, R.; Vredenburgh, J.; Das, A.; Friedman, H. S.
Article Title: Neurocognitive function in patients with recurrent glioblastoma treated with bevacizumab
Abstract: Neurocognitive decline is a frequent adverse effect of glioblastoma. Antitumor therapies that are efficacious, as measured by traditional endpoints such as objective response (OR) and progression-free survival (PFS), and have beneficial effects on neurocognitive function (NCF) are of clinical benefit to these patients. We evaluated neurocognitive changes across time in 167 patients with recurrent glioblastoma treated with bevacizumabbased therapy in BRAIN, a phase II, randomized, multicenter trial. All patients underwent MRI and neurocognitive testing at baseline and every 6 weeks thereafter. Memory, visuomotor scanning speed, and executive function were evaluated using the Hopkins Verbal Learning Test-Revised, the Trail Making Test, and the Controlled Oral Word Association test, respectively. NCF relative to baseline for patients with an OR, PFS >6 months, or disease progression was evaluated at time of OR, 24 weeks, and time of progression, respectively. For patients with an OR or PFS >6 months, median standardized test scores were examined from baseline to week 24. Most patients with an OR or PFS >6 months had poorer NCF performance compared to the general population at baseline and had improved or stable NCF at the time of response or at the 24-week assessment, respectively; most patients with progressive disease had neurocognitive decline at the time of progression. For patients with an OR or PFS>6 months, median standardized test scores were largely stable across the first 24 weeks on study. Neurocognitive testing was an objective, valid, and feasible method of monitoring NCF in patients with recurrent glioblastoma. © The Author(s) 2011. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved.
Keywords: adult; controlled study; treatment outcome; treatment response; major clinical study; bevacizumab; cancer patient; neuroimaging; nuclear magnetic resonance imaging; recurrent cancer; progression free survival; quality of life; phase 2 clinical trial; randomized controlled trial; opiate; irinotecan; multicenter study; glioblastoma; cognition; anticonvulsive agent; corticosteroid; psychologic test; mental performance; psychostimulant agent; cognitive function; controlled oral word association; hopkins verbal learning test revised; nervous system function; visuomotor coordination
Journal Title: Neuro-Oncology
Volume: 13
Issue: 6
ISSN: 1522-8517
Publisher: Oxford University Press  
Date Published: 2011-06-01
Start Page: 660
End Page: 668
Language: English
DOI: 10.1093/neuonc/nor024
PROVIDER: scopus
PMCID: PMC3107095
PUBMED: 21558074
Notes: --- - "Export Date: 17 August 2011" - "CODEN: NEURJ" - "Source: Scopus"
Citation Impact
MSK Authors
  1. Lauren E Abrey
    276 Abrey